The COVID-19 pandemic has a significant impact on nearly every aspect of ordinary life worldwide. There is an urgent need to establish tool sets to facilitate the generation of therapeutic agents as well as vaccines. In this webinar, Sino Biological focused on the design, strategy, process, and troubleshooting in generating high-quality viral proteins via recombinant protein expression technologies as well as the multi-strategic effort for generating anti-viral antibodies for serological diagnostic applications.

Technical Resource

In this complimentary guide, specific case studies will be conducted on the problems encountered in the development of recombinant proteins in several common expression systems, including expression host choice, vectors, expression fragments, culture condition and purification, etc.

In this guide, you can learn the technical information about antibody development, from immunization, technology platform selection, antibody screening to quality validation, and an in-depth overview of featured technology platforms for monoclonal antibody development, including traditional hybridoma technology and phage display based on recombinant method.